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Abstract: Rollout of routine HIV-1 viral load monitoring is
hampered by high costs and logistical difﬁculties associated with
sample collection and transport. New strategies are needed to over-
come these constraints. Dried blood spots from ﬁnger pricks have been
shown to be more practical than the use of plasma specimens, and
pooling strategies using plasma specimens have been demonstrated to
be an efﬁcient method to reduce costs. This study found that
combination of ﬁnger-prick dried blood spots and a pooling strategy
is a feasible and efﬁcient option to reduce costs, while maintaining
accuracy in the context of a district hospital in Malawi.
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INTRODUCTION
The World Health Organization recommends routine HIV
viral load (VL) monitoring of patients on antiretroviral therapy
(ART).1 As clinical and immunologic criteria for treatment fail-
ure have comparatively low sensitivity and positive predictive
values (PPVs),2–5 VL monitoring enables earlier detection of
ART failure, preventing emergence of drug resistance, enabling
timely switching to second-line regimens (if indicated), and pre-
venting inappropriate switching to second-line regimens.6–8
In most resource-limited settings, VL monitoring is not
currently available because of logistic and cost constraints.9
Logistic constraints include the need for an efﬁcient sample
transport system, a reliable cold chain, and phlebotomists to
draw venous blood (VB) for plasma, the standard sample type
for VL testing. Use of dried blood spots (DBS) prepared from
either ﬁnger prick (FP) or ethylenediamine tetraacetic acid–
anticoagulated VB provide a practical alternative to plasma
testing.10,11 DBS samples can be stored at room temperature
for at least 1 month.10 Using FP DBS does away with the
need for phlebotomy, enabling task shifting to lower staff
cadres, where skilled human resources are scarce. A recent
study conducted in Malawi found good correlation between
VL results from plasma and DBS using the NucliSENS
EasyQ HIV-1 v2.0 assay (bioMérieux, Marcy l’Etoile,
France).11
Other recent studies have shown that pooled testing
methods can achieve substantial cost reductions without com-
promising test accuracy.12–17 Testing VL on pooled DBS sam-
ples could reduce logistic and cost constraints, restricting access
to VL testing, if shown to have satisfactory accuracy compared
with individual plasma testing.
This study aimed to determine the efﬁciency, cost
savings, and accuracy of pooled VL testing compared with
individual plasma testing using 2 mini pooling methods,
using pooled FP DBS, VB DBS, and plasma samples.
METHODS
Setting
The study was carried out from August to November
2012 at the district hospital in Thyolo, a rural district in
southern Malawi. The district has a population of approxi-
mately 620,000 and an HIV prevalence of 14.5%.18 At the
end of 2012, 35,000 patients were on ART, of whom 0.2%
were on a second-line regimen.18
The VL testing laboratory at Thyolo District Hospital
became operational in April 2011. VL monitoring replaced
CD4 monitoring of patients attending the hospital ART clinic
and was later extended to patients attending other health
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facilities in the district. VL monitoring coverage was approx-
imately 15% by the end of 2012. Patients with a VL $1000
copies per milliliter receive an adherence intervention and
a repeat VL test 3 months later. Patients with a repeat VL
$5000 copies per milliliter are considered for second-line ART.
Study Population
Three hundred ﬁfty patients participated in the study.
All HIV-positive patients older than 18 years, on ART for at
least 6 months, and having VB drawn as part of their clinical
management were eligible to participate. Ethics approval was
obtained from the Malawi National Health Sciences Research
Committee and the Médecins Sans Frontières Ethics Review
Board. All participants provided written informed consent.
Sample Collection and Preparation
Each participant provided an FP DBS sample and a tube
of VB. A laboratory technician drew blood in to a BD
Vacutainer EDTA tube (Becton Dickinson Vacutainer Sys-
tems, Franklin Lakes, NJ); this was used to prepare VB DBS
and plasma samples. Laboratory technicians prepared 5 FP
DBS and 5 VB DBS samples per participant by applying 50
mL of blood on Whatman 903 ﬁlter paper cards (Whatman,
Maidstone, United Kingdom). DBS samples were dried over-
night and stored at room temperature in separate plastic bags
with desiccants and humidity indicator cards until tested.
Within 3 hours of collection, after preparing VB DBS sam-
ples, the remainder of the EDTA blood was centrifuged at
3000g for 10 minutes. Plasma was transferred to sterile poly-
propylene tubes and stored at 220°C until testing.
Pooling Strategies
The “minipool” and “minipool + algorithm” strategies
used pools of 5 samples, as previously described.13 Seventy
sets of minipools were constituted from the 350 sets of samples.
Plasma pools were constituted by pooling 100 mL of plasma
from 5 patients, for a total volume of 500 mL. DBS pools were
constituted using 2 circles of 50-mL of blood per patient
eluted in 2-mL lysis buffer and pooling 400-mL eluates from
5 patients. Pooled samples were analyzed according to standard
operating procedures.
As each pool contained 5 samples, a pool VL threshold
of 1000 copies per milliliter was used to assess the accuracy
and efﬁciency of pooling for identifying patients with a VL$
5000 copies per milliliter and a pool VL threshold of 200
copies per milliliter was used to assess the accuracy and efﬁ-
ciency of pooling for identifying patients with a VL $1000
copies per milliliter. These thresholds were chosen because
they were in clinical use.
Minipool Strategy
Using the minipool strategy, pools with a VL result
above the threshold were deconvoluted by testing individual
samples from each patient represented in the pool.
Minipool + Algorithm Strategy
Using the minipool + algorithm strategy, pools with
a VL result above the threshold were deconvoluted by serial
testing of individual samples from patients represented in the
pool, in random order, and subtracting individual test results
from the pool result until the VL of the pool had been
accounted for.
For both pooling strategies, pools with a VL result less
than the threshold were not deconvoluted, and all patients
with samples in these pools were considered to have a VL
lesser than the individual threshold.
VL Assay
Quantitative HIV-1 RNA VL testing was performed
with the NucliSENS EasyQ v2.0 assay (bioMérieux). The
assay has a lower limit of detection of 50 copies per milliliter
using a plasma input volume of 0.5 mL, and 800 copies per
milliliter using a DBS input volume of 0.1 mL.
Statistical Analyses
VL in individual plasma samples served as the reference
for all calculations of accuracy and efﬁciency. Accuracy was
determined by calculating sensitivity, speciﬁcity, PPV, and
negative predictive value (NPV). Relative efﬁciency was
deﬁned as 1 minus the average number of tests performed
divided by the number of samples. Cost savings were
calculated with a reagent price of $30 per test, the local price
at the time of the study. Exact binomial 95% conﬁdence
intervals were calculated. P values were calculated using
2-sample tests of proportion. Statistical tests were 2 sided at
alpha = 0.05. All analyses were performed using Stata version
11 (StataCorp, College Station, TX).
RESULTS
Of the 350 participants in the study, 70.5% were
women and 16.3% had suspected treatment failure identiﬁed
on clinical grounds. Their median age was 38 years [inter-
quartile range (IQR): 30–46], and median time on ART was
37 months (IQR: 18–65).
Of the participants, 82.0% had an undetectable individual
plasma VL, 10.0% had a detectable VL ,1000 copies per
milliliter and 8.0% had a VL $1000 copies per milliliter,
including 6.6% with a VL $5000 copies per milliliter. Com-
pared with patients having routine VL monitoring, participants
with clinically suspected treatment failure were less likely to
have a plasma VL ,1000 copies per milliliter (86.0% vs.
93.2%; P = 0.066), and more likely to have a plasma VL
$5000 copies per milliliter (12.3% vs. 5.5%; P = 0.057).
Efficiency of Pooled Testing
The efﬁciencies of the 2 minipooling strategies with
each sample type are shown in Table 1. For example, with FP
DBS and a 5000 copies per milliliter threshold, mini pooling
would reduce the number of tests required by 51.4% com-
pared with testing individual plasma samples. There were no
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statistically signiﬁcant differences in the efﬁciency of the 2
algorithms (P . 0.05), although the minipool + algorithm
was slightly more efﬁcient than the minipool strategy at a
1000 copies per milliliter threshold with pooled plasma and
FP DBS samples. Pooling plasma was more efﬁcient than
pooling DBS at the 1000 copies per milliliter threshold
(P , 0.002), but similar at the 5000 copies per milliliter
threshold (P $ 0.45). There were no statistically signiﬁcant
differences in efﬁciency between FP DBS and VB DBS sam-
ples (P $ 0.22).
Accuracy of Pooled Testing
The accuracies of the 2 minipool strategies in combi-
nation with each sample type are shown in Table 2. NPV
ranged from 97.3% to 100%, and PPV ranged from 96.2%
to 100%, despite the limited sensitivity (range, 60.9%–
69.6%) of pooled DBS samples at the 5000 copies per milli-
liter threshold.
DISCUSSION
This study combined the use of DBS and pooling
strategies for quantitative HIV-1 VL determination. In
Thyolo, approximately 23,000 VL tests are currently required
per year to attain full VL monitoring coverage in accordance
with the national guidelines, which recommend VL testing
6 and 24 months after starting ART and every 24 months
thereafter. At a reagent price of $30 per test and a 5000 copies
per milliliter threshold, pooling DBS samples would save
$345,000 per year by reducing the number of tests required
by approximately 50%. At a 1000 copies per milliliter
threshold, pooling DBS samples would reduce the number
of tests required by approximately 30%, saving $207,000 per
year. As the cost of VL reagents varies across countries in the
region, ranging from $11 to $90 per test19 because of differ-
ences in failure rates, cost savings would vary according to
the setting. For if too many positives “poison” your pools, the
saving will also be diminished. In each context, potential
costs and beneﬁts need to be balanced when choosing thresh-
olds. Although raising the threshold produces greater savings,
TABLE 2. Accuracy of Minipooling and Minipooling + Algorithm Strategy for Detecting an Elevated Viral Load (VL) at 1000 and
5000 copies/mL Thresholds as Compared With Individual Plasma VL (N = 350)
Pooled Sample
Type
VL Threshold
(copies/mL)
Pooling
Strategy
Individual VL Above
Threshold (%)
Sensitivity
(95% CI)
Speciﬁcity
(95% CI) PPV (95% CI) NPV (95% CI)
Plasma 1000 Minipool 8.0 96.4 (81.7 to 99.4) 100 (98.9 to 100) 100 (87.2 to 100) 99.7 (98.3 to 100)
FP DBS 1000 Minipool 8.0 78.6 (59.0 to 91.7) 100 (98.9 to 100) 100 (84.6 to 100) 98.2 (96.1 to 99.3)
VB DBS 1000 Minipool 8.0 89.3 (71.8 to 97.7) 99.7 (98.3 to 100) 96.2 (80.4 to 99.90) 99.1 (97.3 to 99.8)
Plasma 5000 Minipool 6.6 100 (85.2 to 100) 100 (98.9 to 100) 100 (85.2 to 100) 100 (98.9 to 100)
FP DBS 5000 Minipool 6.6 69.6 (47.1 to 86.8) 100 (89.9 to 100) 100 (79.4 to 100) 97.9 (95.7 to 99.2)
VB DBS 5000 Minipool 6.6 60.9 (38.5 to 80.3) 100 (98.9 to 100) 100 (76.8 to 100) 97.3 (95.0 to 98.8)
Plasma 1000 Minipool +
algorithm
8.0 92.9 (76.5 to 99.1) 100 (98.9 to 100) 100 (86.8 to 100) 99.4 (97.8 to 99.9)
FP DBS 1000 Minipool +
algorithm
8.0 78.6 (59.0 to 91.7) 100 (98.9 to 100) 100 (84.6 to 100) 98.2 (96.1 to 99.3)
VB DBS 1000 Minipool +
algorithm
8.0 89.3 (71.8 to 97.7) 99.7 (98.3 to 100) 96.2 (80.4 to 99.9) 99.1 (97.3 to 99.8)
Plasma 5000 Minipool +
algorithm
6.6 95.7 (78.1 to 99.9) 100 (89.9 to 100) 100 (84.6 to 100) 99.7 (98.3 to 100)
FP DBS 5000 Minipool +
algorithm
6.6 69.6 (47.1 to 86.8) 100 (89.9 to 100) 100 (79.4 to 100) 97.9 (95.7 to 99.2)
VB DBS 5000 Minipool +
algorithm
6.6 60.9 (38.5 to 80.3) 100 (89.9 to 100) 100 (76.8 to 100) 97.3 (95.0 to 98.8)
NPV, negative predictive value; VB DBS, venous blood dried blood spot.
TABLE 1. Relative Efficiencies of Different Pooling Methods, With Different Sample Types, at Thresholds of 1000 and 5000 copies
per milliliters
Sample
Type
1000 copies/mL 5000 copies/mL
Mini pool (95%
CI)
Mini pool + Algorithm
(95% CI)
Relative
Efﬁciency, P
Mini pool
(95% CI)
Mini pool + Algorithm
(95% CI)
Relative
Efﬁciency, P
Plasma 44.3 (39.0–49.7) 51.4 (46.1–56.8) 0.059 48.6 (43.2–53.9) 54.0 (48.6–59.3) 0.151
FP DBS 28.6 (23.9–33.6) 34.6 (29.6–39.8) 0.088 51.4 (46.1–56.8) 54.6 (49.2–59.9) 0.405
VB DBS 32.9 (28.0–38.1) 35.7 (30.7–41.0) 0.426 51.4 (46.1–56.8) 53.4 (48.0–58.7) 0.596
CI, conﬁdence interval; FP DBS, ﬁnger prick dried blood spot; VB DBS, venous blood dried blood spot.
Pannus et al J Acquir Immune Defic Syndr  Volume 64, Number 2, October 1, 2013
136 | www.jaids.com  2013 Lippincott Williams & Wilkins
it also reduces the sensitivity of pooled VL testing at detecting
treatment failure.
Several factors need to be considered when choosing
between the minipool and minipool + algorithm strategies.
Although the minipool + algorithm had a slightly higher efﬁ-
ciency than the minipool strategy at the 1000 copies per
milliliter threshold, this advantage of the minipool + algorithm
is offset by several disadvantages, including the greater com-
plexity of the algorithm; a greater probability of false-negative
individual VL results in pools with more than 1 sample above
the individual threshold because of interassay variability, and
a longer average run time because serial testing of individual
samples used in deconvolution of positive pools requires up to
5 extra runs compared with 1 extra run using the mini pooling
strategy. Despite slightly lower cost-savings, implementation
of the minipool strategy may be operationally more feasible
than implementing the minipool + strategy in resource-limited
settings.
The use of DBS samples may enable task shifting to
lower cadres, resulting in human resource allocation efﬁcacies.
The prevalence of treatment failure in the patient population
also needs to be considered when developing algorithms for
pooled testing. Pooling methods become less efﬁcient as the
prevalence of treatment failure increases.
Previous pooling studies have found similar efﬁciencies
using plasma or dried plasma spots as the sample type.12–17
One study that used pooled VB DBS found lower efﬁciencies
and NPVs with pooled VB DBS than with plasma.15 In con-
trast to other studies, our study compared VL results from both
FP DBS and VB DBS pools with individual plasma VL results.
Our ﬁndings are important as they address 2 of the
major obstacles to the rollout of routine VL testing in resource-
limited settings, namely the high cost of individual VL testing
and the logistic difﬁculties associated with sample collection
and transport.9 Although point-of-care VL tests may play an
important role in increasing access to VL monitoring in the
future,20 the use of DBS, tested at a district or central labora-
tory, is a feasible alternative to plasma testing and maybe more
suitable and cost efﬁcient than point-of-care VL testing in some
settings, particularly those requiring high-throughput testing.
Strengths of this study include the sample size and
using the same laboratory technicians to perform all tests in 1
laboratory. In addition, our ﬁndings demonstrate that consti-
tuting, testing, and resolving of positive pools are feasible in
a rural district hospital laboratory. Implementing pooling
strategies will help with the scale-up of routine VL monitoring,
which in turn will increase costs saved as a result of pooling.
VL monitoring provides a direct measurement of
response to ART and is more reliable than CD4 monitoring
at detecting treatment failure. As more patients are initiated
on ART at higher CD4 thresholds, as a result of changes in
ART guidelines, VL monitoring will become the only reliable
method of determining response to treatment. This study
demonstrates that the use of FP DBS or VB DBS combined
with pooled testing using the NucliSENS assay and provides
a feasible option to facilitate the rollout of routine VL
monitoring in resource-limited settings.
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